Association between risk of obstructive sleep apnea severity and risk of severe COVID-19 symptoms: insights from salivary and serum cytokines

• Published in: Frontiers in public health Vol. 12; p. 1348441
• Main Authors: Dinh, Yen, Alawady, Abdullah, Alhazmi, Hesham, Altabtbaei, Khaled, Freire, Marcelo, Alghounaim, Mohammad, Devarajan, Sriraman, Al Mulla, Fahd, Bin-Hassan, Saadoun, Alqaderi, Hend
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 21-02-2024
• Subjects: COVID-19; Cytokines; Humans; IL-6; Interleukin-6; obstructive sleep apnea; Polysomnography; Public Health; SARS-CoV-2; Sleep Apnea, Obstructive - diagnosis; COVID-19; obstructive sleep apnea; SARS-CoV-2; cytokines; IL-6
• ISSN: 2296-2565; 2296-2565
• DOI: 10.3389/fpubh.2024.1348441

Obstructive sleep apnea (OSA) can adversely affect the immune response through clinical factors such as hypoxia, inflammation, and sleep disturbance. Since SARS-CoV-2 heavily relies on local and systemic host immune responses, this study aims to examine the links between the severity of OSA risk, cytokine levels, and the severity of symptoms associated with SARS-CoV-2 infection.
Saliva and blood samples from 50 COVID-19 patients and 30 non-infected hospital staff members were collected. Using Luminex multiplex analysis, 65 blood and salivary cytokines were examined from the collected samples. Ordinal logistic regression analysis was utilized to examine the association between the self-reported risk of OSA, assessed through the STOP-Bang questionnaire, and the likelihood of experiencing severe symptoms of COVID-19. Mann-Whitney test was then performed to compare the cytokine levels between individuals with moderate to severe risk of OSA to those with a mild risk of OSA.
Ordinal logistic regression analysis revealed that individuals with a moderate to severe risk of OSA were 7.60 times more likely to experience more severe symptoms of COVID-19 compared to those with a mild risk of OSA (OR = 7.60, 95%CI: 3.03, 19.06,
< 0.001). Moreover, among COVID-19-positive patients with a moderate to severe risk of OSA, there was a statistically significant negative correlation with serum IL-6 (
 < 0.05), Eotaxin (CCL11) (
 = 0.04), and salivary MIP-3α/CCL20 (
 = 0.04). In contrast, individuals without COVID-19 who had a moderate to severe risk of OSA exhibited a significant positive correlation with serum IL-6 (
 = 0.04).
Individuals with moderate to severe risk of OSA were more likely to experience severe COVID-19 symptoms than those with mild risk for OSA. Additional analysis from the present studies revealed distinct patterns of oral and systemic immune responses between individuals with mild and moderate to severe risk of OSA. Findings from the present study underscores the importance of early detection and management of OSA to improve clinical outcomes, particularly when faced with the subsequent superimposed infection such as COVID-19.